These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32893006)

  • 21. BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation.
    Rathod D; Fu Y; Patel K
    Eur J Pharm Sci; 2019 Oct; 138():105039. PubMed ID: 31394259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of
    Li Z; Lim SL; Tao Y; Li X; Xie Y; Yang C; Zhang Z; Jiang Y; Zhang X; Cao X; Wang H; Qian G; Wu Y; Li M; Fang F; Liu Y; Fu M; Ding X; Zhu Z; Lv H; Lu J; Xiao S; Hu S; Pan J
    Front Oncol; 2020; 10():574525. PubMed ID: 33324552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway.
    Ottis P; Palladino C; Thienger P; Britschgi A; Heichinger C; Berrera M; Julien-Laferriere A; Roudnicky F; Kam-Thong T; Bischoff JR; Martoglio B; Pettazzoni P
    ACS Chem Biol; 2019 Oct; 14(10):2215-2223. PubMed ID: 31553577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glutathione-Scavenging Nanoparticle-Mediated PROTACs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects.
    Liu HJ; Chen W; Wu G; Zhou J; Liu C; Tang Z; Huang X; Gao J; Xiao Y; Kong N; Joshi N; Cao Y; Abdi R; Tao W
    Adv Sci (Weinh); 2023 Jun; 10(16):e2207439. PubMed ID: 37066758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Versatile Nano-PROTAC-Induced Epigenetic Reader Degradation for Efficient Lung Cancer Therapy.
    Zhang HT; Peng R; Chen S; Shen A; Zhao L; Tang W; Wang XH; Li ZY; Zha ZG; Yi M; Zhang L
    Adv Sci (Weinh); 2022 Oct; 9(29):e2202039. PubMed ID: 35988145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands.
    Xu H; Kurohara T; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y
    Bioorg Med Chem; 2023 May; 86():117293. PubMed ID: 37126968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs.
    Steinebach C; Bricelj A; Murgai A; Sosič I; Bischof L; Ng YLD; Heim C; Maiwald S; Proj M; Voget R; Feller F; Košmrlj J; Sapozhnikova V; Schmidt A; Zuleeg MR; Lemnitzer P; Mertins P; Hansen FK; Gütschow M; Krönke J; Hartmann MD
    J Med Chem; 2023 Nov; 66(21):14513-14543. PubMed ID: 37902300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiation responsive PROTAC nanoparticles for tumor-specific proteolysis enhanced radiotherapy.
    Xu M; Yun Y; Li C; Ruan Y; Muraoka O; Xie W; Sun X
    J Mater Chem B; 2024 Mar; 12(13):3240-3248. PubMed ID: 38437473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and Characterization of a Novel Cereblon-Recruiting PRC1 Bridged PROTAC Degrader.
    Kabir M; Qin L; Luo K; Xiong Y; Sidi RA; Park KS; Jin J
    J Med Chem; 2024 Apr; 67(8):6880-6892. PubMed ID: 38607318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL.
    Piya S; Yang Y; Bhattacharya S; Sharma P; Ma H; Mu H; He H; Ruvolo V; Baran N; Davis RE; Jain AK; Konopleava M; Kantarjian H; Andreeff M; You MJ; Borthakur G
    Leukemia; 2022 May; 36(5):1261-1273. PubMed ID: 35173274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Galactose-decorated liver tumor-specific nanoliposomes incorporating selective BRD4-targeted PROTAC for hepatocellular carcinoma therapy.
    Saraswat A; Vemana HP; Dukhande VV; Patel K
    Heliyon; 2022 Jan; 8(1):e08702. PubMed ID: 35036599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach.
    Chen Q; Liu C; Wang W; Meng X; Cheng X; Li X; Cai L; Luo L; He X; Qu H; Luo J; Wei H; Gao S; Liu G; Wan J; Israel DI; Li J; Dou D
    ACS Chem Biol; 2023 Jan; 18(1):25-33. PubMed ID: 36606710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
    Mu X; Bai L; Xu Y; Wang J; Lu H
    Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53.
    Hines J; Lartigue S; Dong H; Qian Y; Crews CM
    Cancer Res; 2019 Jan; 79(1):251-262. PubMed ID: 30385614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A PROTAC Augmenter for Photo-Driven Pyroptosis in Breast Cancer.
    Huang D; Zou Y; Huang H; Yin J; Long S; Sun W; Du J; Fan J; Chen X; Peng X
    Adv Mater; 2024 May; 36(21):e2313460. PubMed ID: 38364230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TRIP12 promotes small-molecule-induced degradation through K29/K48-branched ubiquitin chains.
    Kaiho-Soma A; Akizuki Y; Igarashi K; Endo A; Shoda T; Kawase Y; Demizu Y; Naito M; Saeki Y; Tanaka K; Ohtake F
    Mol Cell; 2021 Apr; 81(7):1411-1424.e7. PubMed ID: 33567268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
    Hu R; Wang WL; Yang YY; Hu XT; Wang QW; Zuo WQ; Xu Y; Feng Q; Wang NY
    Eur J Med Chem; 2022 Jan; 227():113922. PubMed ID: 34700270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRD4 degrader ARV-825 produces long-lasting loss of BRD4 protein and exhibits potent efficacy against cholangiocarcinoma cells.
    Lu Q; Ding X; Huang T; Zhang S; Li Y; Xu L; Chen G; Ying Y; Wang Y; Feng Z; Wang L; Zou X
    Am J Transl Res; 2019; 11(9):5728-5739. PubMed ID: 31632543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors.
    Fan H; Zhou Z; Yu D; Sun J; Wang L; Jia Y; Tian J; Mi W; Sun H
    Bioorg Chem; 2023 Nov; 140():106793. PubMed ID: 37683536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural basis of PROTAC cooperative recognition for selective protein degradation.
    Gadd MS; Testa A; Lucas X; Chan KH; Chen W; Lamont DJ; Zengerle M; Ciulli A
    Nat Chem Biol; 2017 May; 13(5):514-521. PubMed ID: 28288108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.